Home » Newsletters » BioWorld Science

BioWorld Science

July 12, 2018

View Archived Issues

Exosomes deliver no-NO arginase in diabetes

Novel TZD CMHX-008 maintains insulin sensitization with minor effects on weight gain and bone loss

Feeding findings may hold key to appetite control

Achillion initiates first-in-human study of ACH-5548

Researchers develop a rat model of diabetic cardiomyopathy for cardiovascular evaluation

FDA clears IND for Adagene's phase I study of ADG-106

Investigating isoflavonoids for the potential treatment of obesity and diabetes

[225Ac]DOTA-PEG7-5B1 as pretargeted radioimmunotherapy for pancreatic ductal adenocarcinoma

BioSight receives clearance to initiate phase IIb study of BST-236 in AML

Ovid Therapeutics initiates phase II ROCKET trial of OV-101 in fragile X syndrome

Tegsedi approved in the E.U. for the treatment of hATTR

First patient dosed in phase II study of CV-301 plus nivolumab in metastatic colorectal cancer

Recursion set to begin phase I study of AI/ML-based drug candidate, REC-994

Advaxis withdraws conditional MAA for axalimogene filolisbac, advances ADXS-HOT program

Argenx presents phase II data for ARGX-113 in myasthenia gravis

OG-716, a lantibiotic that is active against Clostridium difficile infections

Amgen describes new beta-secretase inhibitors

National Center for Global Health and Medicine, Kumamoto University and Yamasa patent antivirals

Galapagos, AbbVie discover CFTR modulators

Pivotal study of KP-415 in children with ADHD meets primary efficacy endpoint

New phase II trial explores voclosporin ophthalmic solution for dry eye syndrome

Genmab and Immatics partner on next-generation bispecific cancer immunotherapies

New phase III trial investigates etripamil for termination of spontaneous PSVT

TAS-114 combined with S-1 shows preliminary efficacy in pretreated advanced gastric cancer patients

Japanese researchers present phase II data on TAS-205 in patients with DMD

Phase III maintenance trial of Ninlaro in multiple myeloma meets primary endpoint

Phase III study of Imbruvica in treatment-naive DLBCL misses primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...